STAT Plus: Amgen’s KRAS-blocking drug shows minimal effect in colon cancer patients
ANNIE CAVANAGH/WELLCOME
The drug, known as AMG510, has generated significant interest since the release of data showing its potential to shrink tumors in lung cancer patients.
No hay comentarios:
Publicar un comentario